Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study

Slični predmeti

• Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies
  od: Mease, PJ, i dr.
  Izdano: (2024)
• Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
  od: McInnes, IB, i dr.
  Izdano: (2023)
• Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
  od: Coates, LC, i dr.
  Izdano: (2024)
• Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
  od: Merola, JF, i dr.
  Izdano: (2022)
• Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
  od: Philip J. Mease, i dr.
  Izdano: (2024-08-01)